ere’s what we’re looking out for this week in the worlds of pharma and biotech:

CRISPR goes to court

On Tuesday, the warring factions in the CRISPR patent dispute will make their cases to a panel of US Patent and Trademark Office judges in Alexandria, Va. At stake are millions of dollars in licensing fees — plus bragging rights to one of the biggest discoveries in recent science history. Sharon Begley, STAT’s senior science writer, will be there.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.